See more : Agrios Global Holdings Ltd. (AGGHF) Income Statement Analysis – Financial Results
Complete financial analysis of Myovant Sciences Ltd. (MYOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myovant Sciences Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Launch Technologies Co., Ltd. (8420.TWO) Income Statement Analysis – Financial Results
- WeTrade Group, Inc. (WETG) Income Statement Analysis – Financial Results
- PT Tourindo Guide Indonesia Tbk (PGJO.JK) Income Statement Analysis – Financial Results
- Medifast, Inc. (MED) Income Statement Analysis – Financial Results
- Osaka Soda Co., Ltd. (4046.T) Income Statement Analysis – Financial Results
Myovant Sciences Ltd. (MYOV)
About Myovant Sciences Ltd.
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 230.97M | 59.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 51.55M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 179.42M | 57.35M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 77.68% | 96.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 107.40M | 136.71M | 192.56M | 222.61M | 116.83M | 43.50M |
| General & Administrative | 0.00 | 0.00 | 82.33M | 42.22M | 24.23M | 12.36M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 259.36M | 181.42M | 82.33M | 42.22M | 24.23M | 12.36M |
| Other Expenses | 40.04M | 1.66M | 1.62M | -309.00K | 67.00K | -139.00K |
| Operating Expenses | 366.77M | 318.14M | 274.89M | 264.83M | 141.06M | 55.86M |
| Cost & Expenses | 418.32M | 320.10M | 274.89M | 264.83M | 141.06M | 55.86M |
| Interest Income | 384.00K | 211.00K | 2.55M | 881.00K | 0.00 | 0.00 |
| Interest Expense | 13.97M | 10.40M | 12.66M | 8.82M | 2.05M | 0.00 |
| Depreciation & Amortization | 3.46M | 2.69M | 1.77M | 438.00K | 243.00K | 61.00K |
| EBITDA | -183.89M | -258.09M | -273.80M | -255.88M | -140.75M | 0.00 |
| EBITDA Ratio | -79.62% | -435.11% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -187.35M | -260.78M | -270.71M | -264.83M | -141.06M | -55.86M |
| Operating Income Ratio | -81.11% | -439.64% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.59M | 5.99M | -17.51M | -8.25M | -1.98M | -27.66M |
| Income Before Tax | -200.93M | -254.80M | -288.23M | -273.08M | -143.04M | -83.51M |
| Income Before Tax Ratio | -86.99% | -429.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.05M | 336.00K | 761.00K | 476.00K | 213.00K | -74.00K |
| Net Income | -205.98M | -255.13M | -288.99M | -273.55M | -143.26M | -83.44M |
| Net Income Ratio | -89.18% | -430.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| EPS Diluted | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| Weighted Avg Shares Out | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
| Weighted Avg Shares Out (Dil) | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
Myovant Sciences Cancels Second Quarter Earnings Conference Call
MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences
Why Myovant Sciences Stock Is Moving Higher - Myovant Sciences (NYSE:MYOV)
Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
Myovant Sciences: What The Sumitomo Offer Foretells
Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?
Why Myovant Sciences Stock Is Skyrocketing Today
Myovant stock opened 35% up on Monday: here's the catalyst
Myovant Sciences Stock Skyrockets After Rejecting Buyout Offer
Source: https://incomestatements.info
Category: Stock Reports